Sheth R D, Ronen G M, Goulden K J, Penney S, Bodensteiner J B
Department of Neurology and Pediatrics, West Virginia University, Morgantown 26506-9180, USA.
J Child Neurol. 1995 May;10(3):205-8. doi: 10.1177/088307389501000306.
We report our experience with add-on clobazam therapy over a 5-year period in 63 children with refractory epilepsy. The mean duration of epilepsy was 6.7 years. Children were followed for 15 to 64 months. Of 63 children, 57 were developmentally delayed, and 54 had a symptomatic/cryptogenic epilepsy. Forty-one percent became either seizure free or had a greater than 90% reduction in seizure frequency. Seizure frequency was reduced 50% to 90% in another 24%. The average daily dose of clobazam was 0.8 mg/kg. Thirty-five percent had the medication withdrawn for persistent or unacceptable side effects or the development of tolerance (seven patients). Side effects included severe aggressive outbursts, hyperactivity, insomnia, and depression with suicidal ideation. Clobazam is a useful add-on medication for 65% of children with epilepsy. Clinical utility may be limited by behavioral side effects in some patients.
我们报告了63例难治性癫痫患儿接受氯巴占附加治疗5年的经验。癫痫的平均病程为6.7年。对患儿进行了15至64个月的随访。63例患儿中，57例有发育迟缓，54例患有症状性/隐源性癫痫。41%的患儿无癫痫发作或癫痫发作频率降低超过90%。另有24%的患儿癫痫发作频率降低了50%至90%。氯巴占的平均日剂量为0.8mg/kg。35%的患儿因持续或无法接受的副作用或耐受性形成（7例患者）而停药。副作用包括严重的攻击性行为、多动、失眠和伴有自杀观念的抑郁。氯巴占对65%的癫痫患儿是一种有用的附加药物。在一些患者中，临床应用可能会受到行为副作用的限制。
